sitaxentan Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central PubChem repoDB

Active Ingredient History

NOW
  • Now
Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity.   Wikipedia

Chemistry

  • SMILES: Cc1cc2OCOc2cc1CC(=O)c3sccc3S(=O)(=O)Nc4onc(C)c4Cl
  • InChIKey: PHWXUGHIIBDVKD-UHFFFAOYSA-N
  • Mol. Mass: 454.91
  • ALogP: 3.96
  • ChEMBL Molecule:
    sitaxentan  
More Chemistry

Pharmacology

Alternative names

sitaxentan | sitaxsentan

Organizations (41)

Research & Development (41)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Asthma (Phase 2)

Blood Pressure (Phase 2)

General Surgery (Phase 2)

Healthy Volunteers (Phase 1)

Heart Valve Diseases (Phase 2)

Hypertension, Pulmonary (Phase 3)

Lung Diseases (Phase 2)

Proteinuria (Phase 2)

Pulmonary Arterial Hypertension (Phase 3)

Renal Insufficiency, Chronic (Phase 2)

Vasoconstriction (Early Phase 1)

Vasodilation (Early Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial Organizations: 41

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue